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are urgently needed for children orphaned 
by AIDS or living with sick adults. 
For such interventions to be effective and 
accepted, they must be developed through 
the collaboration of researchers, govern-
ments, communities and affected families. 
So scientists need to focus on the messy, 
multifaceted social context of the epidemic, 
not just on the disease itself. 
Support programmes must also be 
properly resourced. Fortunately, organiza-
tions such as Save the Children, UNICEF 
and USAID are already partnering with the 
governments of South Africa, Swaziland, 
Malawi and Ethiopia to ensure that essen-
tial psychosocial interventions are provided. 
These include training community care 
workers in bereavement support. 
The evidence as to which interventions 
are effective is still thin, but we are not start-
ing from scratch. Last year, for instance, a 
collaborative study involving health practi-
tioners from Uganda and Sweden showed 
that depression, anger and anxiety lessened 
in children who had lost one or both parents 
to AIDS if they had access to support groups 
and intensive medical care10. 
Lindiwe has told only her brother and us 
about her diagnosis. She asks whether she 
could call us if she needs to talk to some-
one. What Lindiwe craves is affection, 
acceptance. Her boyfriend loves her but in 
her township, love is Russian roulette: HIV 
prevalence in her age group is 25%. 
A few days after talking to Lindiwe, I spoke 
in a government meeting in Johannesburg. I 
put up a graph showing how non-stigmatized 
children with enough to eat have a 19% risk 
of developing a clinical-level psychological 
disorder; children who are stigmatized and 
hungry have an 83% risk4. I looked up at the 
audience of senior officials. A few of them had 
tears in their eyes. We must win this battle. ■
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A woman receiving her AIDS test result at Kibayi Health Centre in Rwanda. 
Thirty years since the first cases of AIDS were described, there is much to celebrate regarding pro-
gress in the treatment and prevention of 
the disease. Within the past year alone, 
several studies have revealed that anti-
retroviral drugs can prevent the sexual 
transmission of HIV. 
Yet worldwide, many people who are 
potentially exposed to the virus avoid 
finding out whether they carry it, or deny 
that they are at risk of contracting it. Unless 
people establish whether they are infected, 
they will not be able to be adopt the most 
appropriate preventive measures. As scien-
tists and clinicians, our ability to overcome 
this denialism will determine whether we 
ultimately succeed in using combinations 
of all the preventive and therapeutic tools 
now available to slow, and eventually stop, 
the HIV/AIDS pandemic.
During its first decade, the disease 
brought death, pain and suffering, made 
worse by the stigma that accompanied 
infection. As a newly qualified doctor in 
South Africa, it was agonizing for me to 
watch hundreds of patients die from AIDS 
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their tuberculosis or pneumonia infec-
tions and make their last days comfortable. 
Amid this despair, charlatans and ‘snake-oil’ 
cures were plentiful. The real hope among the 
medical community was that science would 
produce a vaccine or a cure. 
This hope was not entirely misplaced. 
The most significant advance in the second 
decade of the epidemic was the develop-
ment of antiretroviral drugs to treat AIDS 
patients and to prevent pregnant women 
from passing on HIV to their children. 
In the late 1990s, ‘triple’ antiretroviral ther-
apy transformed AIDS from a uniformly 
fatal condition to a 
t reatable  chronic 
disease  — but only 
in those countries 
that could afford the 
roughly US$20,000 a 
year that it cost to treat 
each patient. 
For  Afr ica ,  the 
turning point came 
in 2000, at the 13th 
International AIDS Conference in Durban, 
South Africa, when community groups, 
activists, patients, scientists and health-care 
workers jointly protested against drug com-
panies and governments, and called for an 
end to global inequities in access to AIDS 
treatment. Within a few years, antiretroviral 
therapy became a reality throughout most 
of the continent, mainly thanks to funding 
from the Global Fund to Fight AIDS, Tuber-
culosis and Malaria, and the US President’s 
Emergency Plan for AIDS Relief (PEPFAR).
DENYING THE RISK
Events took a different course in South Africa, 
where today 5.4 million people are thought to 
be infected (see graphic) — more than in any 
other country. Until 2004, government hospi-
tals were barred from giving anti retrovirals — 
whether to prevent rape victims from 
acquiring HIV or to treat patients dying from 
AIDS. Thabo Mbeki, South Africa’s president 
at the time, denied that AIDS existed. He and 
his supporters saw the assertion that a new 
sexually transmitted disease was sweeping 
through Africa as a racially motivated attack 
against blacks and a way for pharmaceutical 
companies to exploit the poor. 
Following persistent activism, advocacy, 
litigation and mass mobilization involving 
people living with HIV, the Mbeki gov-
ernment eventually initiated a national 
antiretro viral rollout in 2004. The delay 
caused an estimated 330,000 unnecessary 
deaths and some 35,000 avoidable HIV 
infections in babies1.
Back in 1999, I was asked to join Mbeki’s 
advisory panel, established to assess whether 
HIV causes AIDS. Sitting on that panel, 
engaging in futile debate with AIDS denial-
ists while the epidemic raged on, marked the 
lowest point in my life. I never imagined that 
a decade later, long after Mbeki had stepped 
down, one of the biggest obstacles to curb-
ing the epidemic, both in South Africa and 
throughout the world, would be another 
form of denial — this time at the individual 
and community level. The two kinds of deni-
alism are very different. But both illustrate 
that scientific knowledge and innovation 
alone are not enough to save lives. 
In the epidemic’s third decade, compelling 
evidence accumulated from clinical trials 
that male circumcision reduces the likeli-
hood of men contracting HIV from infected 
women by more than 50%. Last year, my col-
leagues and I showed that an antiretroviral 
drug called tenofovir, formulated as a vagi-
nal gel, reduces the chance of heterosexual 
women contracting HIV by 39% (ref. 2). 
Also in 2010, epidemiologists showed that 
a combination of oral tenofovir and another 
oral antiretroviral, emtricitabine, reduces the 
likelihood of men who have sex with men 
acquiring HIV by 44% (ref. 3). Most prom-
ising of all, the results of a multinational 
clinical trial released last month suggest 
that antiretroviral treatment can reduce the 
transmission of HIV from infected men and 
women to their uninfected partners by 96%.
With these tools — circumcision plus 
antiretroviral drugs that can treat AIDS 
patients, prevent mother-to-child transmis-
sion of HIV and block the sexual transmis-
sion of the virus — stopping the epidemic 
is within our grasp. But only if more people 
acknowledge their risk of contracting HIV 
and find out whether they carry the virus. 
Acknowledging infection risk is a first step 
to getting tested for HIV or taking precautions. 
Risk awareness must be sustained, as taking 
preventive antiretroviral pills or applying the 
microbicidal gel inconsistently can lessen their 
effectiveness. Also, it is crucial that people who 
do take preventive measures know whether 
they already carry HIV, because exposing 
infected individuals to a single antiretroviral 
drug designed to prevent uninfected people 
from contracting the virus could facilitate the 
emergence of drug resistance. 
Moreover, when people know they have 
HIV, they may be less likely to pass on the 
virus to uninfected partners. For instance, 
American men and women who are unaware 
that they carry HIV are 3.5 times more likely 
to transmit the virus to others than those 
who know they are infected4.
GETTING TESTED
Ensuring that people are sufficiently aware 
of their level of risk and that they seek regu-
lar testing for HIV has proved difficult the 
world over.
In South Africa, the most recent national 
HIV survey revealed that 74% of those most 
at risk of acquiring the virus (including 
women aged 20–34) were unaware of their 
HIV status5, even though their answers to 
survey questions indicated that they were 
well informed about the disease. In 2008, the 
United States Centers for Disease Control 
and Prevention (CDC) in Atlanta, Georgia, 
surveyed more than 8,000 men who have 
sex with men, and found that more than 
40% of those infected did not know it6. Rela-
tively few of those at risk who are uninfected 
are taking antiretroviral drugs as a preven-
tive measure7, which the CDC recommends.
The numbers volunteering for HIV tests 
paint a similar picture. Although testing has 
increased significantly in sub-Saharan Africa 
in recent years, only about 20% of men and 
28% of women in South Africa received an 
HIV test and result within the past year. 
Similarly, in Kenya, the 2007 national AIDS 
survey of 18,000 individuals from nearly 
10,000 households found that only 17% of 
those testing HIV positive reported knowing 
that they were infected8. China fares a little 
better: about 44% of people living with HIV 
know that they are infected9. 
Denial is not the only factor hampering 
HIV testing and the use of antiretroviral 
drugs. For instance, in South Africa the 
public health-care system is already over-
whelmed by tens of thousands of AIDS 
patients. Long queues and overstretched 
staff discourage many from trying to obtain 
medical help. But in countries ranging from 
France to India the practical problems ham-
pering testing and uptake of antiretrovirals 
are compounded by people seeking care only 
after they have developed the symptoms of 
full-blown AIDS. 
“We must 
not allow the 
fourth decade 
of the AIDS 
epidemic to 
be the decade 
of missed 
opportunity.”
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We must not allow the fourth decade of the 
AIDS epidemic to be the decade of missed 
opportunity. Every prevention programme 
should involve a combination of interven-
tions tailored to the risks and vulnerabilities 
of the people receiving them. In sub-Saharan 
Africa, for instance, teenage girls are up to 
eight times more likely to contract HIV than 
boys of the same age. For them, a microbicide 
gel that they can control is likely to be critical 
to reducing their risk of infection. Meanwhile, 
male circumcision is likely to have most 
impact for men in their early twenties. 
The challenge is how to implement these 
strategies effectively with the limited funds 
available, so that the successes emerging 
from clinical trials translate into real-world 
benefits. The recent call by the CDC and the 
US National Institutes of Health for propos-
als for ‘implementation science’ programmes 
to address the global epidemic is a step in the 
right direction. Together, these agencies are 
committing about $50 million from PEPFAR 
to programmes involving interventions 
known to be effective in clinical trials, and 
which in combination are likely to improve 
HIV prevention, treatment and care in poor 
communities.
Most important, any programme of 
biomedical interventions should include 
strategies aimed at encouraging people to 
acknowledge their risk of contracting HIV. 
WORKING TOGETHER
We cannot assume that demand for anti-
retroviral drugs, or for any other prevention 
technology, exists just because the need does. 
A government attempt to introduce female 
condoms in South Africa in 1995 illustrated 
the pitfalls of rolling something out without 
concomitantly creating a demand for it. The 
$2.6-million effort to distribute 1.3 million 
condoms to women proved ineffectual 
because patients did not request them and 
health-service providers did not adequately 
promote them. 
South Africa’s era of denialism at the 
highest political level illustrated that sim-
ply giving people facts and information is 
not enough. Fear and avoidance must be 
understood in the context of both the indi-
vidual and society. Health practitioners and 
researchers worldwide must engage local 
communities to find out what factors are 
preventing people from making the best 
choices in terms of prevention and treat-
ment. Community members and patients 
are best placed to advise practitioners how 
to couch advice and information in ways that 
are likely to be effective.
This approach has already proved success-
ful in some cases. For instance, my co-work-
ers and I designed a dosing strategy for the 
tenofovir microbicide gel whereby women 
apply one dose of gel within 12 hours before 
sex and a second as soon as possible within 
12 hours after sex. We selected this strategy 
partly on the basis of scientific information 
about the drug and its effectiveness in animal 
studies — but also as a result of detailed con-
sultations with rural women in South Africa 
revealing that having some flexibility over 
when to apply the gel was essential10. With 
this dosing approach, nearly 900 women 
enrolled in a clinical trial were able to suc-
cessfully apply the gel about 80% of the time2.
An underlying obstacle to finding 
effective ways to intervene is the separa-
tion between biomedical and behavioural 
research in HIV/AIDS. This emanates 
not only from our failure, as researchers, 
funders and clinicians, to fully appreciate 
that every biomedical prevention strategy 
includes a behavioural change, but also 
from counterproductive hierarchies and 
territorialism within science. If behavioural 
and biomedical scientists work together 
to develop solutions, the coming decade 
may prove to be the one when the tide was 
turned against the global AIDS epidemic. ■
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Women attending an HIV clinic in Rwanda avoid the camera.
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